#CancerUpdates - Twitter Hashtag

15 days ago

@heritagemedical @DrAmbrishMithal @drpkchadha @drharpalselhi @DrDhruvchauhan @DrDatta_AIIMS @docakx SHORTAGE OF #Cisplatin & #Carboplatin - #chemotherapy drugs in India - #CancerUpdates @drsthanus @timesofindia @hyderabaddoctor @1DrSushant @ravikarkara

Dr PARVEEN YOGRAJ

@dr_yograj

15 days ago

Turning the Tide: Hope and Action Against Chemotherapy Shortages in India ————————————————— India’s cancer care community is facing a temporary but serious challenge with the shortage of key chemotherapy drugs like cisplatin and carboplatin. Hospitals from AIIMS Delhi to private centres report low stocks, forcing patients and families to search across pharmacies. Doctors rightly warn that prolonged delays can impact treatment outcomes, especially for curative cases involving lung, ovarian, breast, cervical, and other common cancers. Yet, this moment is not one of despair — it is a call for swift, collaborative action. The fallout is real: interrupted cycles can reduce survival chances, increase recurrence risks, and add emotional and financial strain on families, particularly in rural areas where access is already limited. With limited substitutes for these platinum-based drugs, timely intervention is critical to protect ongoing treatments. Pathways to Resolution Positive momentum is building. The government can accelerate emergency imports, fast-track regulatory approvals, and incentivise domestic manufacturers to ramp up production. Pharmaceutical companies must prioritise supply chain transparency and explore alternative sourcing for raw materials amid rising input costs. Hospitals and oncology networks should strengthen coordination — creating regional drug banks, sharing real-time stock data, and prioritising high-need patients. Doctors are already advocating for better forecasting and buffer stocks. Long-term, investing in indigenous R&D, public-private partnerships, and expanding affordable generic manufacturing will build resilience against future disruptions. Patients and families are showing remarkable strength by actively seeking solutions. Community support groups, NGOs, and crowdfunding platforms are stepping up to bridge gaps. With focused policy action and industry commitment, India can quickly stabilise supplies and safeguard cancer care. This challenge highlights the need for a stronger, self-reliant oncology ecosystem. Together — through innovation, collaboration, and compassion — we can ensure no patient is left behind. Hope, backed by decisive steps, will prevail. #CancerCareIndia @IhabFathiSulima @ajaykraina #BeatCancerTogether #HealthcareForAll #HopeInHealing #IndianOncology #StrongerTogether #MedTwitter #MedX #MedEd @Lap_surgeon @docakx

dr_yograj's tweet photo. Turning the Tide: Hope and Action Against Chemotherapy Shortages in India
—————————————————
India’s cancer care community is facing a temporary but serious challenge with the shortage of key chemotherapy drugs like cisplatin and carboplatin. Hospitals from AIIMS Delhi to private centres report low stocks, forcing patients and families to search across pharmacies. Doctors rightly warn that prolonged delays can impact treatment outcomes, especially for curative cases involving lung, ovarian, breast, cervical, and other common cancers. Yet, this moment is not one of despair — it is a call for swift, collaborative action.
The fallout is real: interrupted cycles can reduce survival chances, increase recurrence risks, and add emotional and financial strain on families, particularly in rural areas where access is already limited. With limited substitutes for these platinum-based drugs, timely intervention is critical to protect ongoing treatments.
Pathways to Resolution
Positive momentum is building. The government can accelerate emergency imports, fast-track regulatory approvals, and incentivise domestic manufacturers to ramp up production. Pharmaceutical companies must prioritise supply chain transparency and explore alternative sourcing for raw materials amid rising input costs.
Hospitals and oncology networks should strengthen coordination — creating regional drug banks, sharing real-time stock data, and prioritising high-need patients. Doctors are already advocating for better forecasting and buffer stocks. Long-term, investing in indigenous R&D, public-private partnerships, and expanding affordable generic manufacturing will build resilience against future disruptions.
Patients and families are showing remarkable strength by actively seeking solutions. Community support groups, NGOs, and crowdfunding platforms are stepping up to bridge gaps. With focused policy action and industry commitment, India can quickly stabilise supplies and safeguard cancer care.
This challenge highlights the need for a stronger, self-reliant oncology ecosystem. Together — through innovation, collaboration, and compassion — we can ensure no patient is left behind. Hope, backed by decisive steps, will prevail.
#CancerCareIndia @IhabFathiSulima @ajaykraina #BeatCancerTogether #HealthcareForAll #HopeInHealing #IndianOncology #StrongerTogether
#MedTwitter #MedX #MedEd @Lap_surgeon @docakx

0

8

6

1

563

0

2

0

267

Dr. Neeraj Rajput @NeerajResearch

5 months ago

🎯 Tumor resistance is cancer evolution. Adaptive therapy will define future oncology. #CancerUpdates #PrecisionMedicine #MedTwitter @OncoAlert @myESMO @JCO_ASCO @DrYukselUrun @ScottGottliebMD @FDAOncology @oncodaily @CR_UK @macmillancancer @theNCI

NeerajResearch's tweet photo. 🎯 Tumor resistance is cancer evolution.
Adaptive therapy will define future oncology.
#CancerUpdates #PrecisionMedicine
#MedTwitter @OncoAlert @myESMO @JCO_ASCO @DrYukselUrun @ScottGottliebMD @FDAOncology @oncodaily @CR_UK @macmillancancer @theNCI https://t.co/qFdVX68lRU

0

6

2

0

71

Dr. Neeraj Rajput @NeerajResearch

5 months ago

🎯 Drug resistance isn’t failure it’s tumor evolution. Adaptive therapy is the future of oncology. #CancerUpdates #PrecisionMedicine @OncoAlert @MoHFW_INDIA @US_FDA @WHO @modrnhealthcr @CDSCO_INDIA_INFO @UsHealthdiaries

NeerajResearch's tweet photo. 🎯 Drug resistance isn’t failure it’s tumor evolution.
Adaptive therapy is the future of oncology.
#CancerUpdates #PrecisionMedicine
@OncoAlert @MoHFW_INDIA @US_FDA @WHO @modrnhealthcr
@CDSCO_INDIA_INFO @UsHealthdiaries https://t.co/MWPt7dQk0o

0

3

2

0

42

The Medical Educator Consortium @mecmededucation

5 months ago · Miami

📍 Day 1 at the UCT Meeting in Miami Expert-led discussions with @CParkMD and @PrimoLaraMD covering the latest advances in #ProstateCancer, #BladderCancer, and #GynecologicOncology, alongside @EddieSantosMD and Thomas Herzog. #UCT2026 #Oncology #CancerUpdates @HemSandoval @CParkMD @DrKatyMoore @LuisRaezMD @EddieSantosMD @christine_lovly

Dr. Luis E. Raez

@LuisRaezMD

5 months ago

Day 1 of @mecmededucation UCT meeting in Miami with @CParkMD @PrimoLaraMD discussing the latest in #prostatecancer #bladder #gynecologyoncology @EddieSantosMD Thomas Herzog

LuisRaezMD's tweet photo. Day 1 of @mecmededucation UCT meeting in Miami with @CParkMD @PrimoLaraMD
discussing the latest in #prostatecancer #bladder #gynecologyoncology @EddieSantosMD Thomas Herzog https://t.co/ofaOFblAVI

1

7

2

0

944

0

6

1

0

302

Dr. Neeraj Rajput @NeerajResearch

6 months ago

🎯 Right biomarker → right drug → better survival. Precision oncology is the new standard. #CancerUpdates #PrecisionMedicine @OncoAlert @FDA_Drug_Info @FDAOncology @FDArecalls @hjko_1230

NeerajResearch's tweet photo. 🎯 Right biomarker → right drug → better survival.
Precision oncology is the new standard.
#CancerUpdates #PrecisionMedicine
@OncoAlert @FDA_Drug_Info @FDAOncology @FDArecalls @hjko_1230 https://t.co/3WAZOapOVh

0

2

1

0

24

Dr. Neeraj Rajput @NeerajResearch

6 months ago

In prostate & lung cancer, PSMA targeted and EGFR guided therapies are proving one thing clearly: Treat the mutation, not just the tumor location. Biomarker driven oncology is no longer optional it’s standard. 🔁 Repost if you follow cancer research. #CancerUpdates #Targeted

NeerajResearch's tweet photo. In prostate & lung cancer, PSMA targeted and EGFR guided therapies are proving one thing clearly:
Treat the mutation, not just the tumor location.
Biomarker driven oncology is no longer optional it’s standard.
🔁 Repost if you follow cancer research.
#CancerUpdates #Targeted https://t.co/SzD6pJAA9O

0

3

2

0

64

Dr. Neeraj Rajput @NeerajResearch

7 months ago

💊 New Drug Alert: Combination of PARP inhibitor + androgen-deprivation therapy improves survival in advanced prostate cancer by attacking DNA repair + hormones together. Double targeting = stronger outcomes. #ProstateCancer #Oncology #PARPinhibitor #CancerUpdates

NeerajResearch's tweet photo. 💊 New Drug Alert:
Combination of PARP inhibitor + androgen-deprivation therapy improves survival in advanced prostate cancer by attacking DNA repair + hormones together.
Double targeting = stronger outcomes.
#ProstateCancer #Oncology #PARPinhibitor #CancerUpdates https://t.co/cNfcl0pOJM

0

3

2

0

48

Dr. Neeraj Rajput @NeerajResearch

7 months ago

💥 CAR-NK Therapy Breakthrough: Engineered CAR-NK cells show powerful tumor killing with fewer side-effects than CAR-T especially promising for ovarian and lung cancer. Fast, potent, and off-the-shelf. @Dr_Doc_ #CancerResearch #Oncology #Immunotherapy #CancerUpdates

NeerajResearch's tweet photo. 💥 CAR-NK Therapy Breakthrough:
Engineered CAR-NK cells show powerful tumor killing with fewer side-effects than CAR-T especially promising for ovarian and lung cancer.
Fast, potent, and off-the-shelf.
@Dr_Doc_
#CancerResearch #Oncology #Immunotherapy #CancerUpdates https://t.co/qJJ6QWaaiw

0

3

1

105

Dr. Neeraj Rajput @NeerajResearch

7 months ago

Scientists engineer TILs (Tumor-Infiltrating Lymphocytes) that persist longer and kill more aggressively showing promise in melanoma, lung & cervical cancers. Reprogrammed immunity = stronger outcomes. #CancerResearch #Oncology #CancerUpdates @OncoAlert @Dr_Doc_ @UMichRadOnc

NeerajResearch's tweet photo. Scientists engineer TILs (Tumor-Infiltrating Lymphocytes) that persist longer and kill more aggressively showing promise in melanoma, lung & cervical cancers.
Reprogrammed immunity = stronger outcomes.
#CancerResearch #Oncology #CancerUpdates @OncoAlert @Dr_Doc_ @UMichRadOnc https://t.co/r9vJvjP0Fb

0

4

1

0

68

Total Health™ @TotalHealthConf

10 months ago

Big thanks to our Program Chairs for shaping our educational programs! Their leadership ensures impactful updates. Register for free to meet them: https://t.co/IA0zpOZHDF. Boston we are coming for you! 🏙️✈️ #TotalHealth #CancerUpdates #OncologyEducation #ThankYou